Project lead: Jukka Luukkonen, PhD (UEF)
Radiotherapy project lead: Jan Seppälä, Chief Physicist (KUH)
Radiotherapy has long been an important treatment option for cancer with about half of the patients receiving the modality. This therapy approach uses ionizing radiation to...
Nrf2 is a transcription factor mainly involved in combating cellular stress caused by reactive oxygen and nitrogen species. However, Nrf2 is also involved in cancer and cardiometabolic diseases, making it an essential drug target.
Our research group investigates transcription factor crosstalk in cancers. Especially we focus on deciphering the action of steroid receptors and pioneer factors in prostate cancer.
Project lead: Jaana Hartikainen (UEF)
Radiotherapy project lead: Jan Seppälä (KUH)
This prospective multi-center study will include head and neck squamous cell carcinoma (HNSCC) patients treated in curative intent with radiotherapy (RT) only or concomitant chemoradiotherapy ...
'From basic science to translational impact.'
The goal of our junior research group is to improve therapeutics and diagnostics of cardiovascular diseases by understanding the biology behind the diseases. The main focus is in studying vascular anomalies and aortic aneurysms. Particularly ...
01.07.2020 - 31.12.2024
GeneCellNano Flagship develops new biological drugs, so-called ATMP products, biomarkers and diagnostics for diseases with unmet clinical need. New treatments are developed for cardiovascular diseases and age-related macular degeneration, as well as for brain, ovarian and bladder cancer.
, A.I. Virtanen Institute for Molecular Sciences